236 related articles for article (PubMed ID: 23643389)
21. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
Dbouk HA; Pang H; Fiser A; Backer JM
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
[TBL] [Abstract][Full Text] [Related]
22. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
23. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
Ghodsinia AA; Lego JMT; Garcia RL
Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
[TBL] [Abstract][Full Text] [Related]
24. Rare cancer-specific mutations in PIK3CA show gain of function.
Gymnopoulos M; Elsliger MA; Vogt PK
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5569-74. PubMed ID: 17376864
[TBL] [Abstract][Full Text] [Related]
25. Connecting with an old partner in a new way.
Burke JE; Williams RL
Cancer Cell; 2013 May; 23(5):559-61. PubMed ID: 23680139
[TBL] [Abstract][Full Text] [Related]
26. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
[TBL] [Abstract][Full Text] [Related]
27. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
28. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
29. Functional differences between two classes of oncogenic mutation in the PIK3CA gene.
Chaussade C; Cho K; Mawson C; Rewcastle GW; Shepherd PR
Biochem Biophys Res Commun; 2009 Apr; 381(4):577-81. PubMed ID: 19233141
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
31. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.
Rudd ML; Price JC; Fogoros S; Godwin AK; Sgroi DC; Merino MJ; Bell DW
Clin Cancer Res; 2011 Mar; 17(6):1331-40. PubMed ID: 21266528
[TBL] [Abstract][Full Text] [Related]
32. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
33. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic mutations of PIK3CA in human cancers.
Samuels Y; Velculescu VE
Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
[TBL] [Abstract][Full Text] [Related]
35. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.
Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE
Cancer Res; 2011 Apr; 71(7):2706-17. PubMed ID: 21324922
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
37. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
[TBL] [Abstract][Full Text] [Related]
38. PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110α to the Golgi apparatus.
Wang X; Wang L; Zhu L; Pan Y; Xiao F; Liu W; Wang Z; Guo F; Liu Y; Thomas WG; Chen Y
Diabetes; 2013 Feb; 62(2):444-56. PubMed ID: 23086038
[TBL] [Abstract][Full Text] [Related]
39. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
[TBL] [Abstract][Full Text] [Related]
40. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines.
Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR
PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
